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The review describes recent advances in genetics and genomics of postoperative pain, the association
between genetic variants and the efficacy of analgesics, and the role of pharmacogenomics in the selection
of appropriate analgesic treatments for postoperative pain.
Recent findings
Recent genetic studies have reported associations of genetic variants in catechol-O-methyltransferase
(COMT), brain-derived neurotrophic factor (BDNF), voltage-gated channel alpha subunit 11 (SCN11A) and
m-opioid receptor (OPRM1) genes with postoperative pain. The recent pharmacogenetics studies revealed
an association of the organic cation transporter 1 (OCT1) and ATP-binding cassette C3 (ABCC3)
polymorphisms with morphine-related adverse effects, an effect of polymorphisms in cytochrome P450 gene
CYP2D6 on the analgesic efficacy of tramadol and no effect of CYP2C8 and CYP2C9 variants on efficacy
of piroxicam.
Summary
Genetic variants associate with inter-individual variability in drug responses and they can affect pain
sensitivity and intensity of postoperative pain. Despite the recent progress in genetics and genomics of
postoperative pain, it is still not possible to precisely predict the patients who are genetically predisposed
to have severe postoperative pain or who develop chronic postoperative pain.
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Postoperative pain is a major health burden due to
increasing prevalence and inadequate efficacy of
current treatments [1–4]. All patients undergoing
surgery have acute postoperative pain which usually
resolves within days to weeks during wound heal-
ing. Some patients, however, develop chronic post-
operative pain (CPOP), which is usually defined as
pain due to surgery lasting for more than 3 months.
The severity of acute postoperative pain correlates
with the risk of CPOP [5]. Its incidence varies
depending on the type of surgery, criteria for pain
and duration of follow-up. Fletcher et al. [6] have
reported an incidence of moderate to severe CPOP of
11.8% at 1 year after surgery whereas Haroutiunian
et al. [7] reported the incidence of 6–68% for post-
operative neuropathic pain depending on the type
of surgery. Several risk factors are associated with the
development of CPOP such as preoperative pain,
type of surgery, perioperative nerve injury, fear of
surgery, pain catastrophizing, anxiety, expectation
of pain, obesity, young age and sex (female) [8–11].t © 2018 Wolters Kluwe
rs Kluwer Health, Inc. All rights reseSingle nucleotide polymorphisms (SNPs) of several
pain regulating genes have been reported to associ-
ate with increased pain sensitivity and higher risk
for postoperative pain [12–14].
Pharmacogenetics refers to genetic factors that
associate with variation in drug response. The most
studied pharmacogenetic effects on analgesics are
related to the mutations in the m-opioid receptor
gene (OPRM1) [15]. Individuals who are homozy-
gous for the minor allele of the OPRM1 rs1799971
(118A > G) have been reported to need about 30%
more oxycodone to achieve adequate analgesiar Health, Inc. All rights reserved.
rved. www.co-anesthesiology.com
KEY POINTS
 Candidate gene studies have identified genetic variants
in several genes that might predispose patients to more
severe postoperative pain.
 Genetic variants can modulate the severity of
postoperative pain, analgesic efficacy, metabolism,
and adverse events of analgesics.
 Pharmacogenetics can improve pain management by
predicting the individual response to analgesics prior to
therapy and facilitate the development of novel and
more effective pain medication for postoperative pain.
 Larger cohorts using standardized analgesia methods
are needed for future progress in this field.
Pain medicinecompared with the individuals who are homozy-
gous for the major allele [16]. Drugs metabolized
by the CYP2D6 isoenzyme are particularly liable
for significant variation in efficacy between individ-
uals as the CYP2D6 gene is highly polymorphic [17].
Codeine is an excellent example. It is a pro-drug that
needs to be metabolized to morphine for analgesic
efficacy. Due to variation in the activity of CYP2D6,
individuals can produce morphine very efficiently
(ultrarapid metabolizers) or not at all (poor metab-
olizers) [18]. Pharmacogenetics may play a role in
many other functions relevant to pharmacokinetics,
for example in the transporters [19].
In this review, we will discuss the recent advan-
ces in genetics and genomics of postoperative pain,
the association between genetic variants and the
efficacy of analgesics and the important role of
pharmacogenomics in the selection of appropriate
analgesic treatments for postoperative pain.GENETICS OF POSTOPERATIVE PAIN
Advances in genome-wide association studies
(GWAS) have helped to identify the hereditary fac-
tors that might predispose patients to postoperative
pain [20–22]. Despite the advantage of GWAS stud-
ies that are able to genotype thousands of common
genetic variants (>1% frequency in population)
across the genome [14], the large majority of genetic
studies on postoperative pain are still candidate
gene studies focusing on individual gene polymor-
phisms. Emerging next generation sequencing
(NGS) technologies enable identification of both
common and rare genetic variants [23] but are still
to be used for screening of genetic variants in post-
operative pain. Recent genetic studies have focused
on investigating the association of genetic variants
in a limited set of functionally relevant genes with Copyright © 2018 Wolters Kluwer H
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transferase (COMT), brain-derived neurotrophic fac-
tor (BDNF), voltage-gated channel alpha subunit 11
(SCN11A) and m-opioid receptor (OPRM1) genes
have shown evidence of association with postoper-
ative pain.
Mladenovic et al. [24
&
] investigated the associa-
tion between COMT gene polymorphisms and
temporomandibular disorders (TMD), TMD pain
and postoperative pain after third molar surgery.
The COMT SNPs rs6269, rs4633, rs4818 and
rs4680 were associated with pain sensitivity and a
higher risk to develop TMD which has high inci-
dence in young adults after third molar extraction
[25,26]. Targeted genotyping of blood samples from
90 patients with painful TMD and 92 controls was
performed for the COMT SNPs rs6269, rs4680 and
rs165774 revealing an association of AA and AG
genotypes with rs165774 (G>A, intron) polymor-
phism and increased risk of TMD compared with the
GG genotype. In addition, the AA genotype for
rs6269 polymorphism (A>G, 5‘UTR) was associated
with lower postoperative TMD pain and acute pain
at the dental extraction site. These findings suggest
that chronic postoperative TMD pain and acute pain
at the extraction site after third moral surgery may
be associated with COMT rs6269 polymorphism.
Khalil et al. [27
&
] studied the potential effect of
interaction between COMT SNPs (rs6269, rs4633,
rs4818, and rs4680) with OPRM1 rs1799971 poly-
morphism on postoperative pain and opioid con-
sumption in 153 patients after orthopaedic surgery.
It was reported that genetic variants of COMT can
modulate the OPRM1 gene expression and density in
the brain by regulating the level of enkephalin
[28,29]. A significant interaction was observed for
OPRM1 and the low pain sensitivity (LPS) haplotype
of COMT. In patients without the LPS haplotype,
carriers of the AA genotype of OPRM1 were associ-
ated with significantly higher postoperative pain
scores compared with carriers of the G allele.
Patients carrying Met158Met of the COMT rs4680
and AG/GG of the OPRM1 or TT of the COMT rs4633
and the AG/GG of OPRM1 had the highest amount
of opioid consumption. These results suggest that
interactions of OPRM1 and COMT might contribute
to postoperative pain and response to opioids.
Tian et al. [30
&&
] analysed the association of 638
polymorphisms in 54 pain-related genes with CPOP
in 1152 Chinese surgical patients. The patients car-
rying the G allele (Val/Met and Val/Val genotypes)
for SNP rs6265 (Val66Met) in BDNF gene were asso-
ciated with a higher risk of CPOP compared with the
carriers of wild type A allele (Met/Met genotype).
The BDNFMet/Met mice were associated with lower
mechanical allodynia compared with BDNFVal/Valealth, Inc. All rights reserved.
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that BDNF rs6265 polymorphism may be associated
with an increased risk of CPOP.
Sun et al. [31
&
] examined the association of SNPs
in the SCN11A gene with postoperative pain sensi-
tivity in 309 Han Chinese female patients after
gynaecological laparoscopic surgery. In total, 5 SNPs
(rs33985936, rs13080116, rs11720988, rs11709492,
and rs11720013) in SCN11A were associated with
experimental pain sensitivity and minor alleles of
rs33985936 and rs13080116 were linked with
increased postoperative patient-controlled analge-
sia consumption of sufentanil and tramadol (13.2%
increased PCA for rs33985936 C/T compared to C/C
genotype). This finding suggests that SCN11A SNPs
may associate with postoperative pain after gynae-
cological surgery.
Werner et al. [32] performed a GWAS analysis of
neuropathic pain in 613 patients with osteoarthritis
(OA) after total joint replacement. The detected
variants did not pass the genome-wide significance
P-value threshold (5108). The strongest associa-
tion was found for rs887797 variant in protein
kinase C alpha (PRKCA) previously associated with
inflammatory pain [33].
Persson et al. [34] studied the association of
polymorphisms in 13 candidate pain genes (ABCB1,
COMT, PEBP1, CYP2D6, OPRM1, CYP34A, POMC,
MAOB, SCN9A, UGT2B7, SUDS3, TAOK3, VSIG10)
with pain sensitivity after laparoscopic cholecystec-
tomy. Due to the low number of patients (n¼57),
there were no statistically significant differences
after multiple variant analyses based on high and
low intensity pain phenotypes for more than 400
SNPs in 13 candidate genes.PHARMACOGENETICS OF
POSTOPERATIVE PAIN
Pharmacogenetic studies investigate the effect of
genetic variants on the efficacy, metabolism and
adverse effects of drugs, which might result in het-
erogeneous individual responses to drugs [35]. As
long-term opioid administration after surgery can
lead to opioid-induced hyperalgesia [36], pharma-
cogenetics might improve pain management by
predicting the individual response to analgesics
prior to the therapy and could help to develop more
effective analgesics. Recent pharmacogenetics stud-
ies investigated the association of organic cation
transporter 1 (OCT1) and ATP-binding cassette C3
(ABCC3) SNPs with morphine-related adverse
effects as well as the effect of polymorphisms in
cytochrome P450 genes CYP2C8, CYP2C9 and
CYP2D6 on the analgesic efficacy of tramadol and
piroxicam. Copyright © 2018 Wolters Kluwe
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&&
] studied whether the func-
tional polymorphisms in the OCT1 gene are associ-
ated to postoperative morphine-related adverse
effects including respiratory depression (RD) and
postoperative nausea and vomiting (PONV) in 311
children undergoing tonsillectomy. The OCT1
transporter mediates hepatic uptake of cationic
drugs including morphine [38]. It was found that
the OCT1 variant rs12208357 was associated with
PONV whereas SNP rs72552763 was associated
with RD. Previous studies have linked rs12208357
to decreased OCT1 protein expression [39] and
rs72552763 to the increased plasma concentrations
of tropisetron, ondansetron and tramadol [40]. This
study suggests that genetic variants leading to
decreased OCT1 transporter activity and higher
morphine plasma levels are associated with a higher
incidence of morphine-related RD and PONV.
Chidambaran et al. [41
&&
] studied the association
between SNPs in the ATP-binding cassette ABCC3
and morphine-induced RD and pharmacokinetics
(PK) of morphine in two independent cohorts of
children who underwent tonsillectomy (n¼316) or
adolescents after spine surgery (n¼67). The ABCC3
gene encodes for the liver transporter which plays
an important role in morphine metabolism
through glucuronidation to morphine-3-glucuro-
nide (M3G) and morphine-6-glucuronide (M6G)
[42]. Gene-specific analysis of genome-wide geno-
type data identified 7 intronic SNPs (rs35364174,
rs4148412, rs739923, rs733392, rs1978153,
rs7216383, rs886493) in the ABCC3 gene which
were significantly associated with prolonged stay
in the postoperative anaesthesia care unit (PACU)
due to morphine-induced RD. Furthermore, ABCC3
rs4793665 CC genotype was associated with higher
clearance of M3G and M6G compared with CT
and TT genotypes in both tonsillectomy and spine
surgery subjects. This study suggests that ABCC3
variants are associated with postoperative RD, pro-
longed hospital stay and morphine PK, and that
children genetically predisposed for higher risk of
morphine-related RD could be preoperatively iden-
tified in order to use alternative analgesics that are
not transported through ABCC3 transporters.
Stamer et al. [43
&&
] analysed the effect of loss-of-
function polymorphism in the organic cation trans-
porter OCT1 and variants in CYP2D6 on the phar-
macokinetics and analgesic efficacy of the opioid
analgesic tramadol in 205 patients after abdominal
or urological surgery. Genetic variants in CYP2D6
and OCT1 modulate the pharmacokinetics and anal-
gesic efficacy of tramadol [38,44]. Multiple regres-
sion analysis identified that the number of active
OCT1 alleles and CYP2D6 had a significant impact
on tramadol consumption. Furthermore, the loss ofr Health, Inc. All rights reserved.
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Pain medicinefunction SNPs in the OCT1 gene were associated
with reduced tramadol consumption and increased
plasma concentrations of the active tramadol
metabolite (1)O-desmethyltramadol in the patients.
These results suggest the importance of genotype-
dependent pharmacogenetic dosing of tramadol
based on OCT1 and CYP2D6 activity.
Bialecka et al. [45] addressed the effect of inter-
leukin 6 (IL-6) functional polymorphism rs1800795
(G>C) on opioid requirements in OA patients after
total hip replacement (THR). Healthy C allele car-
riers are known to have decreased IL-6 gene expres-
sion and reduced plasma levels of IL-6 compared
with the G allele carriers [46] which might be asso-
ciated with milder inflammation and lower noci-
ceptive stimulation. By genotyping 196 patients
after THR for the IL-6 rs1800795 SNP, it was
observed that patients with GG and GC genotypes
had significantly increased administration of
opioids on days 0, 3 and 4 after THR compared to
patients with CC genotype. This indicates that G
allele and higher IL-6 levels may predispose OA
patients to increased opioid requirements in the
early postoperative phase after THR.
Calvo et al. [47
&
] investigated the association
between polymorphisms in CYP2C8 and CYP2C9
genes with the efficacy of the nonsteroidal anti-
inflammatory drug (NSAID) piroxicam during the
management of postoperative pain following lower
third molar surgery. The elimination half-life of
piroxicam is about 45 h [48]. The carriers of the
CYP2C9 mutant allele 3 (1/3 and 3/3 genotypes)
were previously reported to have slower metabolism
of piroxicam compared with people homozygous for
the wild type allele 1 (CYP2C9 1/1 genotype) [49]
while some SNPs of CYP2C8 such as CYP2C83 were
reported to decrease the metabolism of NSAIDs [50].
Based on genotyping of 105 volunteers, no differ-
ences were found in efficacy of piroxicam and
adverse effects between the carriers of normal and
slow metabolizing CYP2C83 and CYP2C9 alleles
after 4 days administrations. These results indicate
that piroxicam regulates the inflammation after
third molar surgery without influence from CYP
genotypes.
Somogyi et al. [51
&
] studied the contribution of
ethnicity-dependent genetic variability in innate
immune signalling to morphine consumption dur-
ing PCA in 598 Han Chinese, 230 Malay and 133
Indian women after elective caesarean section under
spinal anaesthesia. The incidence of postoperative
pain was significantly higher in Chinese patients
with COMT rs4680 genotypes which was not
observed in Malay and Indian cohorts. Interaction
between ethnicity and OPRM1 variant rs1799971,
Toll-like receptor 2 (TLR2) variant rs3804100 and Copyright © 2018 Wolters Kluwer H
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ability in morphine consumption in the entire
cohort. These findings indicate that innate immune
system might contribute to the variability in post-
operative morphine requirements in an ethnicity-
dependent manner.
Senagore et al. [52
&&
] analysed the effect of phar-
macogenetics-guided selection of analgesics follow-
ing major abdominal surgery within an enhanced
recovery protocol (ERP). The analgesic protocol was
guided based on the assessment of CYP1A2,
CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5,
COMT, OPRM1 and ABCB1 genes which were part
of a diagnostic pain gene panel. The evaluation was
performed for 63 patients undergoing open or lapa-
roscopic colorectal and major ventral hernia surger-
ies and 47 control patients undergoing the same
operations while being managed with standard ERP.
Pharmacogenomic guidance resulted in modifica-
tions of opioid analgesia of the ERP in 80% of the
patients and changes in the choice of NSAID in 56%
of the patients. These changes resulted in a 50%
reduction in opioid consumption and reduced
adverse effects compared with standard ERP.
Yuan et al. [53] investigated the effect of the
pregnane X receptor PXR1B polymorphisms on
CYP3A4 enzyme activity and postoperative con-
sumption of the m-opioid receptor agonist fentanyl
in 287 Han Chinese female patients undergoing
abdominal total hysterectomy or myomectomy.
PXR is a nuclear receptor which regulates the expres-
sion of CYP3A4 [54], the liver enzyme responsible
for the metabolism of fentanyl [55]. There were no
significant differences in the consumption of fenta-
nyl 24 h after surgery, pain scores and the enzyme
activity of CYP3A4 in Chinese female patients based
on the PXR1B haplotypes which might be due to
the low number of patients (n¼95) with complete
clinical data and information regarding CYP3A
enzyme activity.CONCLUSION
In general, the main predictive factor for postopera-
tive pain is type of surgery [56]. Other major factors
include preoperative pain, anxiety and age [8,56].
On an individual basis, genetic variation may play a
significant role in pain intensity and treatment
outcome. However, despite the recent progress in
genetics and genomics of postoperative pain, it is
still not possible to predict how much pain a patient
will have postoperatively. Future genetic studies
should consider recruiting larger patient cohorts
with standardized analgesic protocols in order to
achieve sufficient statistical power to detect genetic
variants associated with postoperative pain. Also,ealth, Inc. All rights reserved.
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utilized to screen for rare genetic variants that can
modulate pain. Furthermore, it is encouraged to
perform meta-analyses of previous studies and to
independently reproduce the findings in different
research groups. Utilizing the novel genome-editing
technologies such as CRISPR/Cas9 should help to
develop new animal models for postoperative pain
which can better model the development of post-
operative pain in humans. The associations between
epigenetic changes and postoperative pain are
poorly understood and require more intensive
research. The emerging diagnostic pain panels can
be used to select more effective analgesic treatments
based on genotype-dependent dosing of analgesics.
Finally, pharmacogenetics might facilitate the
development of novel analgesics for postoperative
pain with less adverse effects by taking into account
the inter-individual variability in drug responses.
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